Findings for Cemiplimab in Advanced or Recurrent Cervical Cancer

January 4, 2019
Danny Rischin, MD, MBBS, FRACP

Danny Rischin, MD, MBBS, FRACP, discussed the results from a phase II trial looking at cemiplimab (Libtayo) in patients with advanced or recurrent cervical cancer.

Danny Rischin, MD, MBBS, FRACP, director of the Division of Cancer Medicine and head of the Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia, discussed the results from a phase II trial looking at cemiplimab (Libtayo) in patients with advanced or recurrent cervical cancer.

Cemiplimab, a PD-1 monoclonal antibody, was given as a single agent, as well as in combination with radiotherapy in a second cohort. Each of the 2 cohorts had a partial response, Rischin notes.